Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PhotoCure ASASTU:PHS +0.89%73 FCF Margin % is 40.42% as of Jun. 2026, which is 1004% above its 10-year median of 3.66. GuruFocus rates STU:PHS with a GF Score™ of 73/100 and a GF Value™ of €6.92 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 962 Drug Manufacturers companies, PhotoCure ASA ranks better than 70.17% on this metric.
FCF Margin % is calculated as Free Cash Flow divided by its Revenue. PhotoCure ASA's Free Cash Flow for the
three
months ended in Jun. 2026 was €5.22 Mil. PhotoCure ASA's Revenue for the
three
months ended in Jun. 2026 was €12.91 Mil. Therefore, PhotoCure ASA's FCF Margin % for the quarter that ended in Jun. 2026 was 40.42%.
The historical data trend for PhotoCure ASA's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:PHS vs ZTS, UTHR, VTRS: FCF Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, PhotoCure ASA's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PhotoCure ASA FCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, PhotoCure ASA's FCF Margin % distribution charts can be found below:
* The bar in red indicates where PhotoCure ASA's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PhotoCure ASA (STU:PHS) has a FCF Margin % of 40.42% as of Jun. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on PhotoCure ASA and its competitors. This is 1004% above median its historical median of 3.66. According to the industry distribution chart, PhotoCure ASA ranks #287 out of 962 companies in the Drug Manufacturers industry, placing it in the top 29.8%.
Is PhotoCure ASA's FCF Margin % too high?
PhotoCure ASA's current FCF Margin % of 40.42% is 1004% above median its 10-year median of 3.66. The Drug Manufacturers industry median FCF Margin % is 2.51. PhotoCure ASA's value of 40.42% is 1510.4% above this industry median. Based on the distribution chart, PhotoCure ASA ranks #287 out of 962 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, PhotoCure ASA has a GF Score™ of 73/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PhotoCure ASA's FCF Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, PhotoCure ASA ranks #287 out of 962 companies for FCF Margin %. This puts PhotoCure ASA in the upper half of its industry. The industry median FCF Margin % is 2.51. PhotoCure ASA's value of 40.42% is 1510.4% above this benchmark. While the company's 10-year median is 3.66 vs. the industry median of 2.51, PhotoCure ASA has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Drug Manufacturers company?
The median FCF Margin % among Drug Manufacturers companies is 2.51, based on 962 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PhotoCure ASA's current FCF Margin % of 40.42% is 1510.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on PhotoCure ASA and its competitors. For the Drug Manufacturers industry, the median FCF Margin % is 2.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PhotoCure ASA's current FCF Margin % is 40.42%, which is 1004% above median its own 10-year median of 3.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PhotoCure ASA stock overvalued right now?
Based on GuruFocus' analysis, PhotoCure ASA (STU:PHS) is currently considered Significantly Undervalued. The stock's GF Value™ is €6.92, compared to a current price of €4.55 — trading 34.3% below its estimated fair value. The current FCF Margin % is 40.42%, which is 1004% above median its 10-year median of 3.66 and 1510.4% above the Drug Manufacturers industry median of 2.51. PhotoCure ASA's overall GF Score™ is 73/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For PhotoCure ASA (STU:PHS), the current FCF Margin % is 40.42% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PhotoCure ASA (STU:PHS) Overvalued in 2026?
Based on GuruFocus' analysis, PhotoCure ASA stock appears to be undervalued.
The current stock price of €4.55 is trading 34.3% below its estimated GF Value™ of €6.92.
GuruFocus considers PhotoCure ASA to be Significantly Undervalued.
Key valuation signals for STU:PHS:
FCF Margin %: 40.42% (1004% above median its 10-year median of 3.66)
GF Value™: €6.92 vs. price of €4.55 (34.3% below fair value)
Industry Position: 1510.4% above the Drug Manufacturers median (#287 of 962)
No single metric tells the full story. See the STU:PHS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PhotoCure ASA is a Norway-based business group associated with the research, development, production, distribution, marketing, and sales of pharmaceutical products and specialty pharmaceutical companies. The technology platform of the company is focused on the field of photodynamic diagnosis and treatment of cancer. The company has two operating segments of the group the Commercial franchise and the Development portfolio. It generates prime revenue from the Commercial franchise segment, which includes Hexvix and Cysview products. Its geographical segments are Nordic countries, Germany, France, Austria, the United Kingdom, BeNeLux, Italy, Other European countries, Canada, and the United States.
73GF Score
Get the complete analysis for STU:PHS
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:PHS has been successfully added to your 
